English | 简体中文 | 繁體中文 | 한국어
Share:
Pulmocide Limited: Pulmocide Raises $30 Million in Series B Financing
Pulmocide Limited: Pulmocide Raises $30 Million in Series B Financing

http://pulmocide.com/wp-content/themes/wordpress-bootstrap/images/pulmocide-logo.gif

Pulmocide Raises $30 Million in Series B Financing

Funding to progress novel wholly-owned compounds for RSV and pulmonary Aspergillosis

London, UK, 20 March 2017: Pulmocide Ltd, the UK-based drug discovery company developing novel compounds designed for inhaled delivery to treat respiratory syncytial virus (RSV) and pulmonary aspergillosis, today announced the completion of a $30.4 million Series B financing round. The round was led by new investor SR One and included Longwood Fund plus existing investors SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation - JJDC, Inc. and Touchstone Innovations plc.

The proceeds will enable Pulmocide to progress its wholly-owned assets through early clinical development.  Pulmocide is on track to deliver proof of concept data in RSV with its highly potent inhaled RSV antiviral agent (PC786) in human RSV challenge and in infants hospitalised with bronchiolitis due to RSV infection.

Pulmocide will also be progressing PC945, a potent azole antifungal for the treatment of pulmonary Aspergillosis, including fungal asthma, pulmonary Aspergilloma, Aspergillus infections in lung transplant recipients and patients with cystic fibrosis.

Dr Garth Rapeport, Chief Executive Officer of Pulmocide, commented: "Respiratory infections are a significant cause of global morbidity and mortality with a high unmet medical need. Pulmocide is developing bespoke inhaled medicines to provide effective and safe therapies for the treatment of RSV and pulmonary Aspergillosis.

"This Series B fundraising will provide us with the capital to advance our two novel compounds through early clinical development; another step closer to a treatment for patients for these debilitating infections. We are delighted by the interest we've received in this round and would like to thank our new and existing shareholders for their support and continued commitment to Pulmocide.  We look forward to providing further pipeline updates as developments progress with our important programmes."

Matthew Foy, Partner at SR One, added: "Pulmocide's core asset is the management team's proprietary expertise in the design of highly potent compounds with extended lung retention time and limited systemic exposure. This has enabled the development of two anti-infective drugs for serious diseases of the lung, where an inhaled therapy should deliver the optimal clinical outcome. SR One is excited to be joining such a strong syndicate of investors to support Pulmocide as it progresses both programmes towards clinical proof of concept."

- Ends -

For further information, please contact:

Pulmocide Ltd
Garth Rapeport, Chief Executive Officer
+44 203 763 9484
admin@pulmocide.com

Consilium Strategic Communications
Mary-Jane Elliott, Ivar Milligan
+44 20 3709 5702
pulmocide@consilium-comms.com

About Pulmocide:
Pulmocide is a privately-held company located in London, developing novel small molecule inhaled medicines for the treatment of life threatening respiratory infections caused by RSV and Aspergillus. The development of potent anti-infective agents with optimal characteristics for lung delivery is highly attractive from a safety and efficacy perspective with the avoidance of systemic liability. This approach offers the prospect of a new generation of safe and tolerated inhaled therapies for patients in areas of high unmet clinical need. Pulmocide's investors include SR One, SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation - JJDC, Inc., Touchstone Innovations plc and Longwood Fund. For more information please visit www.pulmocide.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Pulmocide Limited via Globenewswire

Copyright © Thomson Reuters 2017. All rights reserved.
 Subscribe RSS Feed  
Press Releases
Nordic American Tankers Limited (NYSE:NAT) - Renewal and Filing of Shelf Registration Statement  
June 23, 2017 18:58 ET
NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)  
June 23, 2017 18:00 ET
Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial  
June 23, 2017 16:45 ET
Novo Nordisk A/S: CHMP adopts positive opinion for EU label update of Victoza® based on the LEADER trial  
June 23, 2017 13:40 ET
Medtronic Announces 7 Percent Increase in Cash Dividend  
June 23, 2017 12:45 ET
Sequa Petroleum N.V. Funding Update  
June 21, 2017 00:03 ET
AIR Worldwide Releases Updated Earthquake Model for the United States  
June 19, 2017 18:13 ET
Schrader Cellars Entrusts Constellation Brands with Highly-Coveted, Critically-Acclaimed Wine Portfolio  
June 17, 2017 04:33 ET
Kymab Group Ltd: Kymab appoints Dr Martin Nicklasson as Non-Executive Chair  
June 16, 2017 16:03 ET
NANOBIOTIX : new translational data presented at ASTRO, NCI AND SITC'S Immunotherapy Workshop  
June 16, 2017 03:53 ET
More News >>
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: